%0 Journal Article
%T 非肌层浸润性膀胱肿瘤的临床研究进展<br>Clinical Research Progress of Non-Muscular Invasive Bladder Cancer
%A 李壮
%A 任海林
%J Advances in Clinical Medicine
%P 8096-8101
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.1291166
%X 膀胱癌是泌尿系统常见的恶性肿瘤。根据肿瘤浸润深度可分为非肌肉浸润性膀胱癌(Non-Muscular Invasive Bladder Cancer, NMIBC)和肌肉浸润性膀胱癌(Muscular Invasive Bladder Cancer, MIBC)。大约50%~70%的NMIBC患者会在5年内复发。另外，10%~15%的NMIBC患者将发展为MIBC。本文就NMIBC的病因、手术及术后辅助化疗进行综述。<br />
Bladder cancer is a common malignant tumor in the urinary system. According to the depth of tu-mor invasion, it can be divided into non-muscle invasive bladder cancer (NMIBC) and muscle inva-sive bladder cancer (MIBC). About 50%~70% of NMIBC patients will relapse within 5 years. In ad-dition, 10%~15% of NMIBC patients will develop MIBC. This article reviews the etiology, surgery and postoperative adjuvant chemotherapy of NMIBC.
%K 非肌层浸润性膀胱癌，辅助化疗，经尿道膀胱肿瘤切除术<br>Non-Muscular Invasive Bladder Cancer (NMIBC)
%K Adjuvant Chemotherapy
%K Transurethral Resection of Bladder Tumor (TURBT)
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=55419